Use of urinary pregnanediol 3-glucuronide to confirm ovulation

Steroids

Volumn 78, Issue 10, 2013, Pages 1035-1040

  Ecochard, R ^a,b,c,d   Leiva, R ^g,h   Bouchard, T ^f   Boehringer, H ⁱ   Direito, A ^a,b,c,d   Mariani, A ^e   Fehring, R ^j  

^a HOSPICES CIVILS DE LYON   (France)

^b UNIVERSITÉ DE LYON   (France)

^c UNIVERSITÉ LYON 1   (France)

^d LABORATOIRE DE BIOMÉTRIE ET BIOLOGIE EVOLUTIVE   (France)

^e Service de Pediatrie   (France)

^f UNIVERSITY OF CALGARY   (Canada)

^g BRUYÈRE RESEARCH INSTITUTE   (Canada)

^h UNIVERSITY OF OTTAWA   (Canada)

ⁱ Diagnostic Consulting Network   (United States)

^j MARQUETTE UNIVERSITY   (United States)

more..

Author keywords

Fertility awareness methods; Luteinizing hormone; Menstrual cycle; Natural family planning; Ovulation; Pregnandiol 3 glucuronide

Indexed keywords

LUTEINIZING HORMONE; PREGNANEDIOL; PREGNANEDIOL 3 GLUCURONIDE; UNCLASSIFIED DRUG;

ADULT; ARTICLE; ECHOGRAPHY; HUMAN; HUMAN EXPERIMENT; INFERTILITY; MENSTRUAL CYCLE; NORMAL HUMAN; OBSERVATIONAL STUDY; OVULATION; SIMULATION; URINALYSIS; UTERINE CERVIX MUCUS;

FERTILITY AWARENESS METHODS; LUTEINIZING HORMONE; MENSTRUAL CYCLE; NATURAL FAMILY PLANNING; OVULATION; PREGNANDIOL-3-GLUCURONIDE;

ADULT; FEMALE; FERTILITY; HUMANS; OVULATION; PREGNANEDIOL; PROSPECTIVE STUDIES; ROC CURVE; YOUNG ADULT;

EID: 84884991712     PISSN: 0039128X     EISSN: 18785867     Source Type: Journal    
DOI: 10.1016/j.steroids.2013.06.006     Document Type: Article

References (34)

1. Brown JB. The relationship between urinary oestrogens and oestrogens produced in the body. J Endocrinol 1957;16:202-12.
2. Collins WP, Collins PO, Kilpatrick MJ, Manning PA, Pike JM, Tyler JP. The concentrations of urinary oestrone-3-glucuronide, LH and pregnanediol-3alpha- glucuronide as indices of ovarian function. Acta Endocrinol (Copenh) 1979 Feb;90(2):336-48.
3. O'Connor KA, Brindle E, Miller RC, Shofer JB, Ferrell RJ, Klein NA, Soules MR, Holman DJ, Mansfield PK, Wood JW. Ovulation detection methods for urinary hormones: precision, daily and intermittent sampling and a combined hierarchical method. Hum Reprod 2006 Jun;21(6):1442-52.
4. World Health Organization. Temporal relationships between ovulation and defined changes in the concentration of plasma estradiol-17B, LH, FSH and P. I. Probit analysis. Am J Obstet Gynecol 1980;138:383-90.
5. Bigelow JL, Dunson DB, Stanford JB, et al. Mucus observations in the fertile window: a better predictor of conception than timing of intercourse. Hum Reprod 2004;19:889-92.
6. Billings EL, Billings JJ, Brown JB. Symptoms and hormonal changes accompanying ovulation. Lancet 1972;1:282-4.
7. Stanford JB, Smith KR, Dunson DB. Vulvar mucus observations and the probability of pregnancy. Obstet Gynecol 2003;101:1285-92.
8. Jennings V, Sinai I. Further analysis of the theoretical effectiveness of the TwoDay method of family planning. Contraception 2001 Sep;64(3):149-53.
9. Hilgers TW, Abraham GE, Cavanaugh D. Natural family planning. I. The peak symptom and estimated time of ovulation. Obstet Gynecol 1978;52:575-82.
10. Fehring R. Accuracy of the peak day of cervical mucus as a biological marker of fertility. Contraception 2002;66:231-5.
11. Ecochard R, Boehringer H, Rabilloud M, Marret H. Chronological aspects of ultrasonic, hormonal, and other indirect indices of ovulation. BJOG 2001 Aug;108(8):822-9.
12. Nielsen MS, Barton SD, Hatasaka HH, Stanford JB. Comparison of several onestep home urinary luteinizing hormone detection test kits to OvuQuick. Fertil Steril 2001 Aug;76(2):384-7.
13. Brezina PR, Haberl E, Wallach E. At home testing: optimizing management for the infertility physician. Fertil Steril 2011 May;95(6):1867-78.
14. Park SJ, Goldsmith L, Skurnick J, Wojtczuk A, Weiss G. Characteristics of the urinary luteinizing hormone surge in young ovulatory women. Fertil Steril 2007;88(3):684-90.
15. Direito A, Bailly S, Mariani A, Ecochard R. Relationships between the luteinizing hormone surge and other characteristics of the menstrual cycle in normally ovulating women. Fertil Steril 2013 Jan;99(1):279-85.
16. Sauer MV, Paulson RJ. Utility and predictive value of a rapid measurement of urinary pregnanediol glucuronide by enzyme immunoassay in an infertility practice. Fertil Steril 1991 Nov;56(5):823-6.
17. Denari JH, Farinati Z, Casas PR, Oliva A. Determination of ovarian function using first morning urine steroid assays. Obstet Gynecol 1981 Jul;58(1):5-9.
18. Adlercreutz H, Brown J, Collins W, Goebelsman U, Kellie A, Campbell H, Spieler J, Braissand G. The measurement of urinary steroid glucuronides as indices of the fertile period in women. World Health Organization, task force on methods for the determination of the fertile period, special programme of research, development and research training in human reproduction. J Steroid Biochem 1982 Dec;17(6):695-702.
19. Moffat S. Taking the natural option: As couples search for satisfactory forms of contraception, some 'rediscover' a traditional method; others are introduced to birth control by an unconventional messenger. Los Angeles Times. 1993 Jan 7. [accessed online 01.04.13].
20. Sauer MV, Paulson RJ, Chenette P, Frederick J, Stanczyk FZ. Effect of hydration on random levels of urinary pregnanediol glucuronide. Gynecol Endocrinol 1990 Sep;4(3):145-9.
21. Blackwell LF, Vigil P, Gross B, d'Arcangues C, Cooke DG, Brown JB. Monitoring of ovarian activity by measurement of urinary excretion rates of estrone glucuronide and pregnanediol glucuronide using the Ovarian Monitor, Part II: reliability of home testing. Hum Reprod 2012 Feb;27(2):550-7.
22. Baerwald AR, Adams GP, Pierson RA. Ovarian antral folliculogenesis during the human menstrual cycle: a review. Hum Reprod Update 2012 Jan-Feb;18(1):73-91.
23. Baerwald AR, Adams GP, Pierson RA. A new model for ovarian follicular development during the human menstrual cycle. Fertil Steril 2003 Jul;80(1):116-22.
24. Brown JB. Types of ovarian activity in women and their significance: the continuum (a reinterpretation of early findings). Hum Reprod Update 2011 Mar-Apr;17(2):141-58.
25. Bonner J, Flynn A, Freundl G, Kirkman R, Royston R, Snowden R. Personal hormone monitoring for contraception. Br J Family Planning 1999;24:124-8.
26. May K. Home monitoring with the ClearPlan easy fertility monitor for fertility awareness. J Int Med Res 2001;29(Suppl. 1):14A-20A.
27. Freundl G, Godehardt E, Kern PA, Frank-Herrmann P, Koubenec HJ, Gnoth Ch. Estimated maximum failure rates of cycle monitors using daily conception probabilities in the menstrual cycle. Hum Reprod 2003 Dec;18(12):2628-3331.
28. Khattab AF, Mustafa FA, Taylor PJ. The use of urine LH detection kits to time intrauterine insemination with donor sperm. Hum Reprod 2005 Sep;20(9):2542-5.
29. Bouchard TP, Genuis SJ. Personal fertility monitors for contraception. CMAJ 2011 Jan 11;183(1):73-6.
30. Petsos P, Mamtora H, Ratcliffe WA, Anderson DC. Inadequate luteal phase usually indicates ovulatory dysfunction: observations from serial hormone and ultrasound monitoring of 115 cycles. Gynecol Endocrinol 1987 Mar;1(1):37-45.
31. Hamilton MP, Fleming R, Coutts JR, MacNaughton MC, Whitfield CR. Luteal phase deficiency: ultrasonic and biochemical insights into pathogenesis. Br J Obstet Gynaecol 1990 Jul;97(7):569-75.
32. O'Connor KA, Ferrell R, Brindle E, Trumble B, Shofer J, Holman DJ, Weinstein M. Progesterone and ovulation across stages of the transition to menopause. Menopause 2009 Nov-Dec;16(6):1178-87.
33. Wong CR, Tse HY, editors. Lateral flow immunoassay. New York, NY: Human Press; 2009. p. 1-33.
34. O'Connor KA, Brindle E, Holman DJ, Klein NA, Soules MR, Campbell KL, Kohen F, Munro CJ, Shofer JB, Lasley BL, Wood JW. Urinary estrone conjugate and pregnanediol 3-glucuronide enzyme immunoassays for population research. Clin Chem 2003 Jul;49(7):1139-48.